Rheumatoid arthritis: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 17
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• AKT 0
• STING 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

18+ intézményből 18, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, Egyesült Királyság· EU contribution 4 793 228 EUR· until 2030. szept.· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Svédország· EU contribution 7 995 375 EUR· until 2029. jún.· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, Egyesült Királyság· EU contribution 150 000 EUR· until 2027. nov.

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution 2 499 750 EUR· until 2031. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Izrael· EU contribution 150 000 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Approach for Unloading Knee Joint Cartilage Pressure: Potential Applications in Post-Surgical Rehabilitation (KNEEUL)

  Centre National de la Recherche Scientifique Cnrs· Paris, Franciaország· EU contribution 242 261 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Engineering fibroblast-targeted mRNA therapies as clinically-focused adjuvants for unlocking tissue regeneration in arthritis (Nano-Synergy)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 150 000 EUR· until 2027. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Innate Lymphoid Cell Engagers (ILCEs): Targeting Innate Lymphoid Cells through a Bispecific Engager for the Resolution of Chronic Inflammation

  Universitatsklinikum Erlangen· Erlangen, Németország· EU contribution 150 000 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Precision control of glycosylation to open a new era of therapeutic antibodies (GlycoBoost)

  Kyron.bio· Paris, Franciaország· EU contribution 2 499 540 EUR· until 2027. szept.· 2 countries

10 of 35 running projects, newest first. Listed amounts together: 169,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Frissítve: 2026. júl. 20.

  “The study is being closed early due to insufficient participant enrollment across study sites.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

  NCT05246280· Navidea Biopharmaceuticals· Frissítve: 2025. jan. 23.

  “Sponsor Decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Hoffmann-La Roche· Forrás

• Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors

  NCT07802678· Sint Maartenskliniek· Forrás

• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· AbbVie· Forrás

• CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Forrás

• A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Eli Lilly and Company· Forrás

• Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

  NCT06440629· Diakonhjemmet Hospital· Forrás

• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Eli Lilly and Company· Forrás

• Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

  NCT07554820· Shaikh Zayed Hospital, Lahore· Forrás

• COVID-19 VaccinE Response in Rheumatology Patients

  NCT05080218· Jeffrey Curtis· Forrás

• Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis

  NCT06818045· Hatice Yemenoğlu· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 97
• CRISPR-Cas Systems 1
• Gene Expression Profiling 121
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 52
• Metabolomics 45
• Mass Spectrometry 7
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 58
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 160
• Genome-Wide Association Study 113

• Adult-onset Still's disease and sarcopenia-related traits - muscle mass, strength, and function: A bi-directional Mendelian randomization study.

  Medicine (Baltimore), 2026. nov.

• Rheumatoid Arthritis and Thrombocytopenia: Causal Evidence and Prognostic Implications From Observational and Mendelian Randomization Analyzes.

  Immun Inflamm Dis, 2026. nov.

• Bidirectional Mendelian randomization analysis reveals the causal relationship between rheumatoid arthritis and acute sinusitis.

  Medicine (Baltimore), 2026. okt.

• Proteome-Wide Mendelian Randomization Identifies Therapeutic Targets for Ischemic Stroke.

  Transl Stroke Res, 2026. okt.

• Genetically proxied sex hormones, Sjögren's disease, and broad dry eye disease: A bidirectional two-sample mendelian randomization study.

  Sci Prog, 2026. okt.

• Bidirectional causal associations between Sjögren syndrome and gastrointestinal disorders: A two-sample Mendelian randomization study.

  Medicine (Baltimore), 2026. szept.

• Association between Helicobacter pylori infection and rheumatoid arthritis: Results from the NHANES 1999-2000 and a Mendelian randomization study.

  Medicine (Baltimore), 2026. szept.

• Exploring the link between dietary vitamin C intake and rheumatoid arthritis risk: A mendelian randomization analysis based on the National Health and Nutrition Examination Survey 2009-2018.

  Medicine (Baltimore), 2026. szept.

• Genetic Evidence Linking Circulating Epidermal Growth Factor to Sjögren's Syndrome Risk.

  Clin Lab, 2026. szept.

• Associations between coeliac disease and musculoskeletal conditions: epidemiology and genetic evidence from a large-scale cohort study.

  Clin Rheumatol, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.